Skip to content
DraconiticResearch
Search Sources API
182,469 studies31 sourcesUpdated 6 min ago
Peer-reviewedCC BYMolecular neurodegeneration

Deciphering the metabolome in Alzheimer's disease.

  • Xiaoli Yang1,2
  • Yong Shen3,4,5,6
6 affiliations
  1. 1Program of Bone-Brain Axis Research, Department of Orthopedics, Institute on Aging and Brain Disorders, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
  2. 2Neurodegenerative Disorder Research Center, Hefei National Laboratory for Physical Sciences at the Microscale, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
  3. 3Program of Bone-Brain Axis Research, Department of Orthopedics, Institute on Aging and Brain Disorders, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China. [email protected].
  4. 4Neurodegenerative Disorder Research Center, Hefei National Laboratory for Physical Sciences at the Microscale, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China. [email protected].
  5. 5Center for Excellence in Brain Science and Intelligence Technology, Chinese Academy of Sciences, Shanghai, China. [email protected].
  6. 6Anhui Province Key Laboratory of Biomedical Aging Research, University of Science and Technology of China, Hefei, China. [email protected].
Read full textPDFDOICite

Abstract

Alzheimer's disease (AD), a multifaceted neurodegenerative disease, stands as the most prevalent form of dementia and one of the leading causes of death in the elderly. An increasing body of evidence underscores the intricate link between AD and metabolic disturbances. Metabolomics research has unveiled dysregulations in various metabolites within the brain and body fluids of individuals with AD, shedding light on the disease's metabolic underpinnings. Furthermore, notable correlations were identified between particular metabolites and AD-associated pathologies, as well as cognitive phenotypes, throughout the course of AD progression. Despite these valuable insights, a holistic understanding of the metabolic basis of AD is still scarce. This review examines recent studies investigating metabolome changes in different types of specimens from AD individuals. We presented a summary of the metabolic signatures of AD and the correlation between metabolites and AD-related traits. We then delineated the various biochemical pathways by which metabolites are involved in AD pathogenesis. We hope that this review will provide a basis for the further development of biomarkers and therapeutic strategies for metabolic disorders in AD.

Related

  1. Integrating transcriptome, metabolome and 16S rRNA sequencing to reveal the effect of celastrol on Alzheimer’s disease in rats
    Yan Wang, Lan Liu, Yongcang Zhang +3
    Scientific ReportsPeer-reviewedCC BYFull textPhysiologyDOAJ
  2. Liver-spleen axis: Deciphering a crucial crosstalk in non-alcoholic fatty liver disease progression and therapeutic implications
    Giovanni Tarantino, Vincenzo Citro
    World Journal of GastroenterologyPeer-reviewedCC BY-NC16 citedEpidemiology & public healthOpenAlex
  3. Deciphering Kawasaki disease genetics through next-generation sequencing: A scoping review
    Anoop Kumar, Vaishali Thakur, Manpreet Dhaliwal +5
    World Journal of Clinical PediatricsPeer-reviewedCC BY-NC 4.0Full textClinical trials & evidence synthesisPMC
  4. Association of Nut Consumption with Dementia and Alzheimer’s Disease
    NutrientsPeer-reviewedCC BYFull textNutritionEurope PMC
  5. Potential links between PCOS/PMOS and Alzheimer disease and related dementias
    Journal of the Endocrine SocietyPeer-reviewedCC BYFull textEndocrinology & metabolismEurope PMC

Cite

BibTeXRIS
BibTeX
@article{yang2026deciphering,
  title = {{Deciphering the metabolome in Alzheimer's disease.}},
  author = {Xiaoli Yang and Yong Shen},
  journal = {Molecular neurodegeneration},
  year = {2026},
  month = jul,
  doi = {10.1186/s13024-026-00982-w},
  url = {https://europepmc.org/article/MED/42972409},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Deciphering the metabolome in Alzheimer's disease.
AU  - Xiaoli Yang
AU  - Yong Shen
PY  - 2026
DA  - 2026/07/31
JO  - Molecular neurodegeneration
DO  - 10.1186/s13024-026-00982-w
UR  - https://europepmc.org/article/MED/42972409
AB  - Alzheimer's disease (AD), a multifaceted neurodegenerative disease, stands as the most prevalent form of dementia and one of the leading causes of death in the elderly. An increasing body of evidence underscores the intricate link between AD and metabolic disturbances. Metabolomics research has unveiled dysregulations in various metabolites within the brain and body fluids of individuals with AD, shedding light on the disease's metabolic underpinnings. Furthermore, notable correlations were identified between particular metabolites and AD-associated pathologies, as well as cognitive phenotypes, throughout the course of AD progression. Despite these valuable insights, a holistic understanding of the metabolic basis of AD is still scarce. This review examines recent studies investigating metabolome changes in different types of specimens from AD individuals. We presented a summary of the metabolic signatures of AD and the correlation between metabolites and AD-related traits. We then delineated the various biochemical pathways by which metabolites are involved in AD pathogenesis. We hope that this review will provide a basis for the further development of biomarkers and therapeutic strategies for metabolic disorders in AD.
SN  - 1750-1326
ER  -